The burden of haemocompatibility with left ventricular assist systems: A complex weave

European Heart Journal

Volumn 40, Issue 8, 2019, Pages 673-677

  Mehra, Mandeep R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSISTED CIRCULATION; BIOCOMPATIBILITY; BLOOD FLOW; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; DISEASE BURDEN; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEMOLYSIS; HOSPITALIZATION; HUMAN; MORBIDITY; NOTE; OXIDATIVE STRESS; PERSONAL EXPERIENCE; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; THROMBOSIS; VALIDATION PROCESS; ADVERSE DEVICE EFFECT; CIRCULATION; FEMALE; HEART ASSIST DEVICE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; PROSTHESIS COMPLICATION; PROSTHESIS DESIGN; RISK FACTOR;

BLOOD CIRCULATION; FEMALE; HEART-ASSIST DEVICES; HEMODYNAMICS; HUMANS; PROSTHESIS DESIGN; PROSTHESIS FAILURE; RISK FACTORS; STROKE; VENTRICULAR FUNCTION, LEFT;

EID: 85060352729     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx036     Document Type: Note

References (22)

1. James KK, David CN, Francis DP, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report:15,000 patients and counting. J Heart Lung Transplant 2015;34:1495-1504.
2. Uriel N, Adatya S, Mehra MR. Evolution in mechanical circulatory support: are we at the precipice of a disruptive innovation? J Am Coll Cardiol 2015;66:2590-2593.
3. Heatley G, Sood P, Goldstein D, Uriel N, Cleveland J, Middlebrook D, Mehra MR. MOMENTUM 3 Investigators. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung Transplant 2016;35:528-536.
4. Nascimbene A, Neelamegham S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 2016;127:3133-3141.
5. Netuka I, Kvasnicka T, Kvasnicka J, Hrachovinova I, Ivak P, Marecek F, Bilkova J, Malikova I, Jancova M, Maly J, Sood P, Sundareswaran KS, Connors JM, Mehra MR. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant 2016;35:860-867.
6. Stewart GC, Givertz MM, Mehra MR. Pump thrombosis redux. J Heart Lung Transplant 2015;34:1511-1514.
7. Susen S, Rauch A, Van Belle E, Vincentelli A, Lenting PJ. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost 2015;13:1757-1767.
8. Stulak JM, Davis ME, Haglund N, Dunlay S, Cowger J, Shah P, Pagani FD, Aaronson KD, Maltais S. Adverse events in contemporary continuous-flow left ventricular assist devices. A multi-institutional comparison shows significant differences. J Thorac Cardiovasc Surg 2016;151:177-189.
9. Najjar SS, Slaughter MS, Pagani FD, Starling RC, McGee EC, Eckman P, Tatooles AJ, Moazami N, Kormos RL, Hathaway DR, Najarian KB, Bhat G, Aaronson KD, Boyce SW. HVAD Bridge to Transplant ADVANCE Trial Investigators. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2014;33:23-34.
10. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Myers S, Acker MA, Rogers J, Slaughter MS, Stevenson LW. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS Registry. J Heart Lung Transplant 2015;34:1515-1526.
11. Pagani FD, Milano CA, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Delgado RM, Leadley K, Aaronson KD, Rogers JG. HeartWare HVAD for the treatment of patients with advanced heart failure ineligible for cardiac transplantation: results of the ENDURANCE destination therapy trial. J Heart Lung Transplant 2015;34:S9.
12. Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Marasco S, Beyersdorf F, Damme L, Schmitto JD. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. J Am Coll Cardiol 2015;66:2579-2589.
13. Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC, Colombo PC, Walsh MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants K, Itoh A, Ewald GA, Horstmanshoff D, Long JW, Salerno C; MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med 2017;376:440-450.
14. Saito S, Yamazaki K, Nishinaka T, Ichihara Y, Ono M, Kyo S, Nishimura T, Nakatani T, Toda K, Sawa Y, Tominaga R, Tanoue T, Saiki Y, Matsui Y, Takemura T, Niinami H, Matsumiya G, J-MACS Research Group, J-MACS Research Group. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS. J. Heart Lung Transplant 2014;33:599-608.
15. Moazami N, Steffen RJ, Naka Y, Jorde U, Bailey S, Murali S, Camacho MT, Zucker M, Marascalco PJ, Rao V, Feldman D. SUSTAIN Investigators. Lessons learned from the first fully magnetically levitated centrifugal LVAD trial in the United States: the DuraHeart trial. Ann Thorac Surg 2014;98:541-547.
16. Bartoli CR, Kang J, Zhang D, Howard J, Acker M, Atluri P, Motomura T. Left ventricular assist device design reduces von Willebrand factor degradation: a comparative study between the HeartMate II and the EVAHEART left ventricular assist system. Ann Thorac Surg 2016; pii: S0003-4975(16)30934-1. doi: 10.1016/j.athoracsur.2016.06.112.
17. Dimasi A, Rasponi M, Sheriff J, Chiu WC, Bluestein D, Tran PL, Slepian MJ, Redaelli A. Microfluidic emulation of mechanical circulatory support device shear-mediated platelet activation. Biomed Microdevices 2015;17:117.
18. Muthiah K, Robson D, Macdonald PS, Keogh AM, Kotlyar E, Granger E, Dhital K, Spratt P, Hayward CS. Increased incidence of angiodysplasia of the gastrointestinal tract and bleeding in patients with continuous flow left ventricular assist devices (LVADs). Int J Artif Organs 2013;36:449-454.
19. Lee M, Akashi H, Kato TS, Takayama H, Wu C, Xu K, Collado E, Weber MP, Kennel PJ, Brunjes DL, Ji R, Naka Y, George I, Mancini D, Farr M, Schulze PC. Vascular inflammation and abnormal aortic histomorphometry in patients after pulsatile-and continuous-flow left ventricular assist device placement. J Heart Lung Transplant 2016;35:1085-1091.
20. Moazami N, Dembitsky WP, Adamson R, Steffen RJ, Soltesz EG, Starling RC, Fukamachi K. Does pulsatility matter in the era of continuous-flow blood pumps?. J Heart Lung Transplant 2015;34:999-1004.
21. Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, Takeda K, Takayama H, Fried J, Naka Y, Topkara VK, Colombo PC. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transplant 2016;35:1003-1009.
22. Roever L, Resende ES, Mehra MR. Vulnerable Brain and Ventricular Assist Devices. Stroke 2016;47:2677-2678.